Important NeuMoDx Update

After careful consideration, we have decided to discontinue the development and further commercialization of the NeuMoDx 96 and 288 Molecular Systems.

This decision comes after a thorough review process on the options for the future of these integrated clinical testing platforms. In light of the post-pandemic market developments for these types of systems, the NeuMoDx systems are no longer aligned with our strategic goals.

We understand this decision will likely create inconveniences for our valued customers.

We will continue to provide support to our NeuMoDx customers, including ongoing maintenance, technical support, warranty services and the provision of necessary consumables.

Understanding next steps: FAQs

For how long will QIAGEN continue to support and supply NeuMoDx customers?
  • During a transition period extending into 2025, QIAGEN will continue to provide support for existing NeuMoDx customers.
  • A comprehensive plan has been developed to ensure a smooth transition for all affected customers of their clinical testing needs to third-party suppliers. This includes ongoing maintenance, technical support and the provision of necessary consumables for a specified period.
Will new customer orders for NeuMoDx be accepted?
  • Unfortunately, QIAGEN cannot accept any new instrument orders as of the day of announcement: June, 6 2024.
  • We will be completing production in the fourth quarter of 2024. To ensure a smooth transition, we kindly request your final forecast by early September.
Will QIAGEN continue to develop new assays for NeuMoDx? And what about the assays currently in regulatory submission?
  • QIAGEN will no longer develop NeuMoDx assays.
  • All regulatory submissions for NeuMoDx assays under review by a regulatory body will be withdrawn, and all associated development work and regulatory efforts will be discontinued.
How will the discontinuation affect existing service level agreements (SLAs) and warranties?
  • QIAGEN will support until consumables' shelf life is exceeded or instruments are removed from the field.
Will there be any downtime during the transition, and how will the impact on QIAGEN customers’ clinical operations be minimized?
  • All processes will continue to ensure testing continuity.
  • We will be completing production in the fourth quarter of 2024. To ensure a smooth transition, we kindly request your final forecast by early September.
Can customers choose a transition date? When must the transition be completed?
  • QIAGEN will have conversations with our customers to evaluate suitable solutions for both sides.
To which third-party vendors will NeuMoDx customers be transitioned? Is there a list of suppliers they can choose from?
  • QIAGEN will have conversations with our customers to evaluate suitable solutions for both sides.
What about the patient data customers have generated with NeuMoDx? How will they be transitioned to meet national privacy regulations?
  • Patient data will remain with the customer. QIAGEN will have conversations with our customers to evaluate suitable solutions for both sides.
For how long can customers consult technical service?
  • Products will continue to be supported through the remaining shelf life of consumables.
Contact details
If you have any immediate questions or concerns, please don’t hesitate to contact your local sales representative or our Customer Service Team.
Contact our specialists